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ABSTRACT
Background Congenital deletions affecting 3q11q23
have rarely been reported and only ﬁve cases have
been molecularly characterised. Genotype‒phenotype
correlation has been hampered by the variable sizes
and breakpoints of the deletions. In this study, 14 novel
patients with deletions in 3q11q23 were investigated
and compared with 13 previously reported patients.
Methods Clinical data were collected from 14 novel
patients that had been investigated by high resolution
microarray techniques. Molecular investigation and
updated clinical information of one cytogenetically
previously reported patient were also included.
Results The molecular investigation identiﬁed deletions
in the region 3q12.3q21.3 with different boundaries and
variable sizes. The smallest studied deletion was 580 kb,
located in 3q13.31. Genotype‒phenotype comparison in
24 patients sharing this shortest region of overlapping
deletion revealed several common major characteristics
including signiﬁcant developmental delay, muscular
hypotonia, a high arched palate, and recognisable facial
features including a short philtrum and protruding lips.
Abnormal genitalia were found in the majority of males,
several having micropenis. Finally, a postnatal growth
pattern above the mean was apparent. The 580 kb
deleted region includes ﬁve RefSeq genes and two of
them are strong candidate genes for the developmental
delay: DRD3 and ZBTB20.
Conclusion A newly recognised 3q13.31 microdeletion
syndrome is delineated which is of diagnostic and
prognostic value. Furthermore, two genes are suggested
to be responsible for the main phenotype.
INTRODUCTION
Deletions affecting the proximal long arm of
chromosome 3 are rarely reported in the literature.
Hitherto, 14 patients have been described with
deletions of various sizes and different breakpoints
within the 3q11q23 region. The deletions were
investigated in nine of the patients by standard
karyotyping
1e8 and only ﬁve cases have been
investigated by molecular methods.
9e14 The 14
patients had a range of different phenotypes
including cranial and facial dysmorphisms, devel-
opmental retardation, and genital and peripheral
musculoskeletal abnormalities. However, deter-
mining a proper genotype‒phenotype correlation
has been hampered by the few cases with molec-
ularly deﬁned deletions as well as by the limited
number of patients described.
The advent of high resolution microarray tech-
niques has greatly facilitated the investigation of
chromosomal disorders, enabling the identiﬁcation
of disease-causative genes for known syndromesd
for example, CHARGE syndrome (OMIM 214800)
and 9q subtelomeric deletion syndrome (OMIM
610253) as reviewed in Vissers et al.
15 In addition,
a number of novel microdeletion and micro-
duplications syndromes have been delineated,
starting with the ﬁrst described 17q21.31 micro-
deletion syndrome in 2006 (reviewed in Vissers
et al
15). Moving from a cytogenetic approach to an
ever more sensitive molecular karyotyping has
reversed the strategy behind the identiﬁcation of
novel syndromesdthat is, patients having similar/
overlapping genetic rearrangements are identiﬁed
before the clinical characteristics of a syndrome are
deﬁned. Furthermore, the collection of clinical and
genetic information in databases such as DECI-
PHER,
16 ISCA,
17 and ECARUCA
18 has been crucial
for the comparison between patients with rare
aberrations.
Using a reverse genetics approach and a joint
collaborative effort through DECIPHER, we
describe 14 novel patients carrying microscopic or
submicroscopic deletions in the region 3q12.3q21.3.
In addition, a molecular investigation is presented
of a previously reported 3q-deletion patient.
5 This
study also presents a review of the 13 previously
reported patients. A newly recognised 3q13.31
microdeletion syndrome is identiﬁed, characterised
by developmental delay, postnatal growth above
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Copy-number variationsthe mean, characteristic facial features, and abnormal male
genitalia. The phenotype is associated with a 0.6 Mb critical
region harbouring two strong candidate genes for the develop-
mental delay, the DRD3 and ZBTB20 genes.
PATIENTS AND METHODS
Patients
In the present study, 15 patients were included with deletions in
the proximal long arm of chromosome 3. One patient, case 2,
was previously described clinically and cytogenetically
by Ogilvie et al 1998,
5 while the remaining 14 patients are
novel. Clinical information was systematically collected from
clinicians, using supplementary table 1.
The WHO Child Growth Standards were used to standardise
birth height, weight, and occipitofrontal circumference (OFC)
for all novel patients and for the previously reported patients
where growth parameters were given.
19 WHO standards are
available up to 19 years of age for height and up to 10 years of
age for weight. To assess OFC after birth the German head
circumference references were used, which extend up to 18 years
of age.
20
The clinical investigations and genetic analyses were
performed according to the guidelines in the Declaration of
Helsinki and were approved by the ethics committee of Uppsala
University. Informed consent was obtained from all family
members and speciﬁc permission to publish photographs was
obtained.
Methods
Molecular investigation of the 15 patients was conducted using
different array platforms (table 1 and supplementary material)
according to the manufacturer’s instructions. The identiﬁed
deletions were conﬁrmed using karyotyping or ﬂuorescence in
situ hybridisation (FISH) (supplementary material) and parental
testing was performed when parental DNA was available (13/15
cases). Deletions in cases 1 and 2 were microscopically visible
and had initially been investigated using GTG banding.
5 The
positions of the deletions were mapped to the human NCBI/
hg18 assembly of the UCSC genome browser (http://genome.
ucsc.edu/).
RESULTS AND DISCUSSIONS
Molecular details
We present the clinical and molecular features of 15 novel
patients harbouring deletions of the proximal long arm of
chromosome 3. One of the patients was reported cytogenetically
in the late 1990s
5 (case 2). The present study also provides
a review of 13 previously reported patients.
1e14 The deletions are
Table 1 Molecular characterisation of 3q12q21 deletions in present and previously published patients
Case Chromosomal band Start (hg18) End (hg18) Size (Mb)
No of
RefSeq genes Inheritance Method
Case1 q12.3eq13.31 103332789 118628997 15.30 64 De novo Affymetrix GeneChip 250K Nsp/G-banding
Case2 q12.3eq13.33 103481815 122521004 19.04 89 De novo Affymetrix GeneChip 250K Nsp/G-banding
Case3 q13.11eq13.31 105180963 118326520 13.15 63 De novo 1 Mb clone array/FISH
Case4 q13.11eq21.3 105782523 128177975 22.40 144 De novo Agilent array CGH 400K/Q-PCR
Case5 q13.11eq13.33 105911706 120983616 15.07 78 De novo Agilent array CGH 44K/Q-PCR
Case6 q13.13eq13.33 110116098 122633570 12.52 73 De novo Agilent array CGH 44K/FISH RP11-233L3
Case7 q13.13eq13.31
(inv(3)(q13.1;q26.3))
111722434 117006477 5.28 39 De novo Agilent array CGH 44K/FISH RP11-105H23
Case8 q13.2eq13.32 112976429 120183473 7.2 38 Not tested Affymetrix GeneChip 250K Nsp
Case9 q13.2eq13.31 113680819 116466363 2.79 24 De novo Agilent array CGH 44K/FISH RP11-572C15
Case10 q13.2eq13.31 113764648 116429950 2.67 22 De novo BlueGnome CytochipV2/
FISH RP11-572C15
Case11 q13.2eq13.31 113764648 116429950 2.67 22 De novo BlueGnome CytochipV2/FISH
RP11-572C15 and RP11-58D2
Case12 q13.2eq13.31 114490215 116264578 1.77 15 De novo Affymetrix genome-wide human
SNP Array6.0
Case13 q13.31eq13.31 115335356 115916848 0.58 5 De novo Affymetrix GeneChip 250K Nsp
Case14 q13.31eq13.31 116922662 118098190 1.18 3 Absent
in mother
Agilent Array CGH 44K/FISH RP11-91D11
Case15 q13.32eq21.2 119261437 126585699 7.32 63 De novo SpectralChip CC4-V0.3/FISH RP11-169N13
Kosaki
10 * q12.2eq13.2 101480701 114803431 13.32 70 De novo Spectral Genomics human BAC array 2500/
G-banding
Malan
11 * q13.11eq13.33 104531502 122804242 18.27 91 De novo Agilent 244K/FISH
Simovich
14 * q13.11eq13.12 105652857 108151059 2.50 2 De novo Illumina HumanHap550 Beadchip/FISH
RP11-91B3
Shimojima
13 * q13.2eq13.31 114321633 116406833 1.9 16 De novo Agilent array CGH 105A/FISH
Hou
9/Sato
12 * q11.2eq13.31
t(3;12)(q13.2;p11.2)
97002372 116490074 19.49 107 De novo BAC array CGH/FISH
Lawson-Yuen
4 * q13.1eq13.3 104400000 123400000 De novo Chromosome analysis
Okada
6 * q12eq21 99800000 131500000 De novo G-banding, Q
Fujita
1 * q12eq23 99800000 144400000 De novo G-banding
Genuard
2 * q13.12eq21.3 107800000 131500000 De novo G-banding
Jenkins
3 * q11eq21 91700000 131500000 De novo G-banding
Ogilvie
5 * q12eq21 99800000 131500000 De novo G-banding
McMorrow
7 * q12eq21 99800000 131500000 De novo G-banding, Q and C
Arai
8 * q12eq22 99800000 131500000 De novo
*Previously published cases with the reference indicated; Start- and endpoints in italic indicates maximum estimated start and end.
BAC, bacterial artiﬁcial chromosome; CGH, comparative genomic hybridisation; FISH, ﬂuorescence in situ hybridisation; SNP, single nucleotide polymorphism.
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Copy-number variationsmapped within 3q12.3q21.3 and they range in size from the
smallest of 580 kb (case 13) to the largest of 22.4 Mb (case 4)
(ﬁgure 1 and table 1). Most of the deletions have different
breakpoints, although the breakpoints in cases 9, 10, 11, and 12
are in close proximity (ﬁgure 1); the breakpoints of these
patients are approximately located at 113.5e116.5 Mb. In all but
one case, the deletion was the sole identiﬁed aberration. In case
7, an inversion was identiﬁed (inv(3)(q13.1q26.3)) and the
deletion was located at the 3q13.1 inversion breakpoint. The
deletions showed a de novo occurrence in 13 cases. Parental
DNA was not available for testing in case 8, whose 7.2 Mb
deletion is likely to have arisen de novo because of the size and
gene content of this deleted region. Carrier testing in the parents
of case 14 was only possible in the mother’s DNA, which
revealed a normal chromosome 3.
The shortest region of overlapping deletion (SRO) is delin-
eated by case 13, with estimated breakpoints at genomic
positions 115.33‒115.39 Mb (ﬁgure 1). This 580 kb segment
includes ﬁve RefSeq genes: DRD3, ZNF80, TIGIT, MIR568, and
ZBTB20. The SRO is shared by 13 of the novel patients, and by
11 of the previously reported patientsdthat is, 24 cases in total.
The SRO is within the previously reported smallest deletion
which was 1.9 Mb in size.
13 However, the 2.5 Mb deletion
identiﬁed in the case presented by Simovich et al is located at
3q13.11q12 and hence does not overlap with the region deﬁned
in the present study.
14 Four cases do not have an overlapping
deletion with the SRO, namely case 14, case 15 (both from this
study), Kosaki et al,
10 and Simovich et al.
14
Clinical data
In total, clinical data from 28 patients, both novel and previ-
ously published cases, were collected and are summarised in
supplementary table 1. Photographs of some of the novel
patients (cases 1, 2, 4, 5, 6, 7, 9, 12 and 15) are shown in ﬁgure 2.
The clinical ﬁndings in the 24 patients sharing the SRO (115.33‒
115.39 Mb) are summarised separately, and the frequency of
these features was calculated (supplementary table 1, frequency
column). These features include normal pregnancy and delivery
at term with a few exceptions.
1 451 11 4Developmental delay is
the most prevalent feature, present in 19/21 cases. Two cases did
not suffer from developmental delay (case 7) or had not been
examined at the time of the report due to the patient  s young age
(case 4). However, case 7 displayed attention deﬁcit disorder.
There are eight patients presenting with autism or attention
deﬁcits and one with epilepsy, including case 7. In 15 of 17 cases
speech was delayed, and in three of these 15 patients the speech
was minimal/no meaningful words were used/communication
by hands by the age of 4.5, 8, and 18 years. Muscular hypotonia
was found in 12/15 patients. Interestingly, muscular hypotonia
was suggested by Shimojima et al to be the only common
Figure 1 A physical map of the
chromosomal region 3q11.2 to 3q23,
illustrating the deletions. The deletions
identiﬁed in novel patients are shown in
black, previously reported deletions that
have been molecularly characterised
are shown in dark grey, and previously
reported deletions that have been
cytogenetically characterised are
shown in light grey. RefSeq genes are
indicated in blue. The grey solid box
illustrates the shortest region of
overlapping deleted region, and
a zoomed view shows the ﬁve RefSeq
genes within this region (bottom panel).
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Copy-number variationsﬁnding along with developmental delay in patients with 3q13
deletions
13. The brain and central nervous system were also
affected: ﬁve patients had agenesis of the corpus callosum, three
patients had ventriculomegaly, and one had alobar holopro-
sencephaly. In total, seven patients displayed skull malforma-
tions: two with dolichocephaly, two with plagiocephaly, and
three with brachycephaly. Furthermore, 10/13 patients
presented with broad and prominent forehead.
Distinct recognisable facial features, including short philtrum,
protruding lips with full lower lips and tented upper lips, anti-
mongoloid slanted eyes, and hypertelorism, were apparent in
several cases (ﬁgure 2). In total, the facial features in the 24
patients were short philtrum in 6/6, epicanthal folds in 8/14,
hypertelorism in 7/17, antimongoloid slant in 7/13, a high
arched palate in 7/10, and ptosis in 4/11. Ocular malformation
included strabismus in 6/14 and myopia in 4/8. The ears were
large in 5/15 and were low set in 4/15.
There was a high prevalence of abnormal external male
genitalia, affecting 11/15 males. The abnormalities included
micropenis (4/15), microorchidism (2/15), cryptorchidism (7/
15), and shawl scrotum (2/15). All female patients had normal
genitalia.
Skeletal malformations were a frequent ﬁnding, present in as
many as 16/24 patients. The skeletal malformations included
scoliosis, lordosis, thoracic kyphosis, joint contractures, and
peripheral malformations affecting the hands and feet. Of note
were the proximally set thumbs present in three novel cases
(cases 2, 4, and 9).
Growth parameters were assessed in the 24 patients sharing
the SRO and 4/11 (cases 4, 5, 9, and 10) had a birth OFC >85th
centile (7/11 had a birth OFC >50th centile). OFC was also
available at a later age and 9/20 had an OFC >85th centile (11/
20 had an OFC >50th centile). Case 6 is noteworthy, having
a birth OFC between 15e50th centile and an OFC between
85e97th centile at the age of 4 years and 10 months. The weight
and length parameters were also reviewed and these were
normal at birth, 5/16 had a weight >50th centile, 5/12 had
a length >50th centile, and none of the patients displayed
a weight or length >85th centile. At the time of report, 10/19
had a weight >50th centile and 9/19 had a weight >85th centile.
Regarding height at the time of report, 13/21 were >50th centile
and 10/21 were >85th centile. Hence, a postnatal growth
pattern above the mean was observed among these patients. A
larger region, encompassing 18.2 Mb in q13.11q13.33, has
previously been identiﬁed in a screening of patients with
syndromic overgrowth, and the present report delineates the
overgrowth candidate region to 3q13.31. In DECIPHER, most of
the listed microdeletion/microduplication syndromes are asso-
ciated with short stature, while there is one that is characterised
by tall staturedthe 15q26 overgrowth syndrome. Regarding
OFC, there is one listed microdeletion/microduplication
syndrome in DECIPHER with macrocephaly, the 1q21.1
microduplication syndrome, in comparison with microcephaly
that is present in 13 of the DECIPHER listed syndromes. Known
overgrowth syndromes are Sotos syndrome, Beckwith‒
Wiedeman syndrome, Simpson‒Golabi‒Behmel syndrome,
Figure 2 Photographs of cases 1, 2, 4, 5, 6, 7, 9, 10, 12, and 15. Physical characteristics of note are short philtrum, protruding lips with full lower lips
and tented upper lips, hypertelorism, and antimongoloid slanted eyes present in several cases.
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Copy-number variationsKlinefelter syndrome, homocystinuria and Marfan syndrome.
21
The molecular knowledge about overgrowth syndromes is thus
fairly limited and, in this context, the present report provides
novel clues to ﬁnding genes involved in growth.
Candidate genes
The proximal long arm of chromosome 3 is a gene dense region
(ﬁgure 1) with 145 genes within the estimated boundaries
(chr3:103.32e128.18 Mb) of the 15 novel patients. Hence,
a number of genes could potentially contribute to the pheno-
typic features of these patients. Regarding the ﬁve RefSeq genes
present in the SRO, two (DRD3 and ZBTB20) are particularly
interesting with respect to developmental delay, the neuropsy-
chiatric features, and the structural brain, central nervous
system, and skull malformations. DRD3 encodes D3 subtype of
the dopamine receptors, which is localised to the limbic areas of
the brain, and is involved in locomotion, cognition, emotion, and
affection as well as neuroendocrine secretion.
22 Targeted muta-
tion of DRD3 is associated with hyperactivity in mice, and
recent association studies in patients with neuropsychiatric
disorders have explored the contribution of DRD3 variants to
their phenotype.
23e25 The ZBTB20 gene belongs to the BTB/
POZ zinc ﬁnger family and is expressed in the developing
hippocampal neurons.
26 Downregulation of ZBTB20 disturbs
the normal maturation of a certain type of neurons in the
hippocampus, and changes in the cortical cytoarchitecturedfor
example, lack of the posterior part of the corpus callosumdwere
observed in transgenic mice models.
27 28 One additional inter-
esting aspect of ZBTB20, with respect to the observed postnatal
overgrowth in the patients, is the fact that it regulates genes
involved in growth and metabolism.
29
In addition to the SRO and the genes therein, the present
study provides clues about other 3q genomic regions harbouring
important genes with respect to normal development. First, the
deletion in case 14, telomeric of the SRO, contains LSAMP and
GAP43, two strong candidate genes for developmental delay.
LSAMPencodes the limbic system associated membrane protein,
and studies in both human and mice models have demonstrated
the involvement of LSAMP in neuropsychiatric features and
behaviour.
30 31 GAP43 is involved in neurite outgrowth, neuro-
transmission, and synaptic plasticity among other functions and
GAP43 was also recently identiﬁed as a candidate gene for
autism and autistic-like manifestations in human and mice.
32e34
In addition, Gap43 +/ mice display decreased corpus callosum
and hippocampal commissure volume.
34 Secondly, the present
study supports the previous suggestion that 3q11 could harbour
a locus for agenesis of the corpus callosum (ACC).
23 5Five
previously published 3q deletion patients exist who displayed
ACC.
24573 5Here we present one novel patient (case 6) with
ACC, having a deletion that can help with further reﬁning of the
ACC critical region. As discussed above, strong candidate genes
involved in ACC are ZBTB20 and GAP43.
Further support underlining the importance of DRD3,
ZBTB20, LSAMP, and GAP43 in contributing to the phenotype in
patients with 3q13 deletions is their haploinsufﬁciency score, as
deﬁned by the study by Huang et al.
36 There are 49 genes of the
total of 145 genes in 3q12-q21 that have a haploinsufﬁciency
score of <50%, and these four candidate genes are among those
49 (supplementary table 2).
CONCLUSION
The present study describes a newly recognised 3q13.31 micro-
deletion syndrome based on 24 novel and previously reported
patients and suggests candidate genes responsible for the
developmental delay. In addition, the age of the patients in this
report, ranging from infant to 20 years, provides prognostic
information for patients with this microdeletion syndrome.
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